leadf
logo-loader
viewPressure BioSciences, Inc.

Pressure BioSciences to rebrand as Avalia Bio following merger with Cannaworx and SkinScience Labs

The name change reflects the science-driven collaboration between the companies, which will utilize Pressure Bio’s Ultra Shear Technology to bring new levels of bioavailability and performance to a suite of human, animal and agricultural products

Handshake
The combined Avalia Bio has an IP estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers

Pressure BioSciences Inc (OTCQB:PBIO) announced plans to change its name to Avalia Bio following its acquisitions of and merger with Cannaworx Inc and SkinScience Labs Inc.

The name change is meant to reflect the science-driven collaboration between the companies, which will operate as synergistic divisions utilizing Pressure Bio’s Ultra Shear Technology platform to bring new levels of bioavailability and performance to a suite of human, animal and agricultural products. 

"PBI's UST platform offers the potential to deliver an extraordinary breakthrough in creating unique, high quality nanoemulsions of oil in water,” PBI CEO Richard Schumacher said in a statement. “A vast range of personal care and consumption products, including nutraceuticals, cosmetics, pharmaceuticals, food & beverages, all face the perplexing challenge of getting active oil-based nutrients or therapeutic ingredients to become easily absorbable and effective in the water-based biology of our bodies.”

READ: Pressure Biosciences boosted as it announces deal to acquire SkinScience Labs and award-winning products

Cannaworx and its principals have 12 products, including several that utilize the company’s patented and patent pending hemp-derived phytocannabinoid formations for pain relief. 

The parties believe UST processing will increase the efficacy of Cannaworx products, reduce manufacturing costs, increase profits and distinguish its product lines.

"My co-founder in Cannaworx is [SkinScience Labs President] Dr Adrienne Denese, MD, Ph.D., the founder, innovator and spokesperson behind over $500M in Dr Denese SkinScience product line sales for the past 17 years on QVC,” Cannaworx President Bobby Ghalili said. “These skin care and anti-aging products are part of our planned rollup of companies under Availa Bio. In our rapidly expanding line of innovative human, veterinary and agricultural products, several of which incorporate phytocannabinoids from hemp oil, we are utilizing our own oral and topical proprietary bioavailability and absorption delivery technology.”

Over the next few months, the plan is to roll out two patented oral phytocannabinoid formulations for pain relief allowed under an FDA OTC monograph. 

The combined Avalia Bio has an IP estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers.

"My decades of development and marketing of skin care and anti-aging products that meet the scrutiny and demands of an extremely loyal following of consumers has always required us to be leaders in quality and performance, not just for results but in the entire product experience perceived by our users,” Denese said. “We quickly realized that the Ultra Sheer Technology platform offered the opportunity to improve not only the performance of our existing, highly-regarded formulations, but also to achieve new heights within the entire cosmetics industry."

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Pressure BioSciences, Inc.

Price: 1.62 USD

OTCMKTS:PBIO
Market: OTCQB
Market Cap: $5.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

3 min read